OncBioMune, AqVida add additional drugs to distribution agreement (Paclitaxel and Oxaliplatin)

BATON ROUGE, LA--(Marketwired - June 15, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces an exclusive distribution and licensing agreement between OncBioMune and AqVida GmbH ("AqVida"), a Germany-based FDF manufacturer specializing in the development, registration, manufacturing and distribution of generic pharmaceutical products, with an emphasis on the field of cancer therapy from their state-of-the-art facility in Dassow, Germany.

As released on 4/26/2017, AqVida granted OncBioMune the rights to several oncology and other generic pharmaceuticals in their portfolio, including imatinib, docetaxel and azathioprine to name a few, for commercialization in the Mexican markets. As an addendum to the agreement, the companies have agreed to expand the portfolio adding Paclitaxel for the treatment of breast, ovarian, lung, bladder, prostate, melanoma, esophageal, Kaposi's sarcoma, as well as other types of solid tumor cancers and Oxaliplatin which is uses to treat colon and rectal cancer that has spread (metastasized).

AqVida has commericialized these products for sale in the European markets. AqVida will support OncBioMune's efforts through providing all requisite documentation for seeking marketing approval in Mexico and manufacturing the products at their GMP-certified facility in Germany.

Additionally, OncBioMune and AqVida are conducting negotiations regarding expanding the exclusive licensing agreement to cover commercialization in the Mexican markets the complete AqVida portfolio of medicines, including several used for treating the most common types of cancer.

Furthermore, AqVida has expressed interest in being involved in the development of ProscaVax, OncBioMune's novel therapeutic cancer vaccine currently undergoing clinical trials as a new treatment for prostate cancer. The two companies are contemplating a joint venture in which AqVida would be integral in the clinical development of ProscaVax in Europe, including leading the initiation of clinical studies and manufacturing ProscaVax for use within the highly regulated E.U. market.

"This agreement helps us become a self-sufficient company and a major generic provider in Latin America," commented Andrew Kucharchuk, President and Chief Financial Officer at OncBioMune. "AqVida has a strong presence in Europe and in the oncology space, giving us another high-quality partner with deep experience in bringing new drugs to market globally. The relationship with AqVida will allow us to commercialize the products at competitive prices, which we believe will result in capturing a meaningful market share across the board."

"As successful as our generics are throughout Europe, there is a large, untapped market in Mexico for which OncBioMune is an ideal partner to capitalize with its extensive distribution network and experience with the regulatory pathway," said Wolfgang Heinze, CEO at AqVida. "We further see many other synergies between our companies for leveraging resources to introduce our other generics to Mexico and Latin America and to develop ProscaVax for the vast European markets. Approximately 400,000 new cases of prostate cancer are diagnosed each year in Europe and over 92,000 lives are lost annually to the disease. Radical prostatectomy remains a leading therapy and we are of the opinion that a safe and effective new treatment would be warmly welcomed across the entire union. We'd like to be a part of developing such a therapy."

Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.

About AqVida GmbH

AqVida is a German oncology FDF manufacturer that is fully dedicated and specialized in the development, registration, manufacturing and distribution of finished dosage forms mainly for the oncology sector. It has developed a portfolio of medicines for treating the most common types of cancer. AqVida's expertise in generic oncology products has made the company a leading partner in the pharmaceutical industry. AqVida works alongside some of the leading names in the oncology sector. In co-operation with its partners, AqVida has achieved substantial development and growth with its oncology portfolio. AqVida is a pharmaceutical company with an impressive track record in fulfilling all client requirements from API sourcing through to EU market release for finished products. Teams of experts in development, regulatory affairs, patent issues and laboratory work bring skills and knowledge together to achieve optimum results for customers. AqVida complies with all German and EU legal requirements for the pharmaceutical industry and is GMP certified by the German Health Authorities. As a European organization, AqVida has the knowledge and resources to provide regulatory support to meet the requirements of the complex and highly regulated EU market.

About OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals is a revenue-stage biopharmaceutical company engaged the development of novel cancer immunotherapy products, including a proprietary vaccine technology designed to stimulate the immune system to attack tumor cells without damaging healthy tissue. OncBioMune is also involved in drug development and commercialization internationally through our wholly-owned subsidiary, OncBioMune México, S.A. De C.V. Our lead pipeline product, ProscaVax™, is scheduled to commence two, separate mid-stage clinical trials in 2017: a Phase 2 for early-stage prostate cancer at a major Northwest U.S. university cancer research hospital and a Phase 2/3 study in Mexico for late-stage prostate cancer patients. OncBioMune has a portfolio of targeted and licensed therapies, some of which are biosimilars and generics to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceuticals' actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals' need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical's vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.